-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As subclinical hyperthyroidism can increase the risk of osteoporosis and fractures, people are increasingly worried about the long-term safety of thyroid-stimulating hormone (TSH) suppression therapy for bones in patients with differentiated thyroid cancer (DTC) after total thyroidectomy.
.
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
Researchers aim to determine the effect of TSH suppression therapy on bone mineral density (BMD) in patients with DTC
Researchers searched PubMed, Embase, Cochrane Library and other data sources
.
Eligible observational studies included DTC patients receiving TSH suppression therapy and BMD measurement
The study included a total of 17 studies (739 patients and 1085 controls) for quantitative analysis
.
In postmenopausal women, TSH suppression therapy can significantly reduce the BMD of LS (-0.
03; -0.
05, -0.
02), and a similar trend was observed in TH treatment
Evidence from observational studies suggests that postmenopausal women receiving TSH suppression therapy are at risk of reduced BMD
Original source:
Eu Jeong Ku.
et al.
Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis .
JCEM.
2021.
https://doi.
Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis in this message